Source: Annual Congress 2010 - Biomarkers for lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
A. Muñoz Lucas, M. Caamaño Somoza, J. Jareño Esteban, I. de Granda Orive, B. Carrillo Aranda, J. A. Maldonado Sanz, A. Aguilar Ros, C. Civera Tejuca, J. L. Lopez Colon, L. M. Callol Sanchez (Madrid, Spain). Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data. Eur Respir J 2010; 36: Suppl. 54, 3245

Member's Comments

No comment yet.

Related content which might interest you: Detection of differences in volatile organic compounds (VOCs) by ion mobility spectrometry (IMS) of exhaled breath in patients with interstitial lung diseases (ILDs) compared to healthy controls (HC) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Electronic nose (E-nose) analysis of exhaled volatile organic compounds (VOCs) distinguishes pediatric patients (pts) with Cystic fibrosis (CF) from healthy controls (HC) and depicts disease status Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Volatile organic compounds (VOCs) in exhaled air of patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 208s Year: 2003 Volatile organic compounds (VOC) in exhaled breath of patients with COPD Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010 Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Volatile organic compounds (VOC) in exhaled air sampled through the working channel of a bronchoscope in lung cancer patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer, using the analytical technique thermal desorber- gase chromatography-spectrometer mases Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Volatile organic compounds (VOCs) in COPD patients with exacerbation Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function Source: International Congress 2015 – The next generation of lung function tests Year: 2015 Expiratory flow rate and breath hold affect exhaled volatile organic compounds (VOC) in healthy subjects Source: Annual Congress 2012 - Exhaled biomarkers to assess airway inflammation Year: 2012 Volatile organic compounds (VOC) in non-small-cell lung cancer (NSCLC) Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort Source: Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020 Year: 2021 Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values Source: International Congress 2014 – The assessment of comorbidities Year: 2014 New contributions in the determination of volatile organic compounds (VOC) in lung cancer (LC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Detection and variability of cytokine-levels in exhaled breath condensate (EBC) of patients with stable COPD Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003